DNB Health Care is an equity fund managed by DNB in the Sektor – Helse category. Actively managed global health care fund from DNB covering the whole sector,…
About this fund
Categorised as Sektor – Helse, DNB Health Care is an equity fund from DNB.
The fund: 26 years of track record, running since 2000 (share classes may be younger).
Rune Sand-Holm has been on the fund since 2020.
Measured on return so far this year measured in NOK as of 13.11.2026, the fund is number 7 of 18 in its category.
Tracking error against its benchmark is 4.0%.
The manager states a volatility of 15.4% for the fund.
DNB Health Care is an actively managed, global equity fund in the health care sector, with a track record back to 2000. The management company is DNB Asset Management in Oslo, the fund arm of DNB, Norway's largest bank. The company is indirectly wholly owned by DNB Bank ASA.
Investment philosophy
The fund covers health care services, pharmaceuticals, medical equipment and biotechnology globally. The managers state that the USA is a substantial part of the health care market and that the fund normally has a significant share of its investments there. The mandate is broader than that of DNB's biotechnology fund and DNB's thematic fund for women's health.
The managers
Rune Sand-Holm is the lead manager and has managed the fund since April 2020. He has been an analyst at Nordea and Carnegie and holds a master's in finance from BI. Benedicte Kilander Bakke has managed the fund since February 2018. She trained as a dentist at the University of Oslo, holds an MBA from NHH and has a background in the pharmaceutical industry, including Pfizer and Novartis. Anesa Mulabecirovic Sahnoun became a manager in May 2026, after being an analyst on the fund since June 2021. She holds a doctorate in medicine from the University of Bergen and an MBA from NHH, and has worked as a physician at Haukeland University Hospital. The managers are based in Oslo and are part of DNB Asset Management's health care team, which also manages DNB Bioteknologi, where Bakke is lead manager, and DNB Fund Women's Health, launched in August 2026 with Mulabecirovic Sahnoun as lead manager.
The portfolio
The portfolio is more concentrated than comparable funds, with fewer holdings and heavy weight in the largest, most established companies. The centres of gravity have been pharmaceuticals, biotechnology and life sciences, medical equipment and health care services, with the USA as the largest country. Lasting top holdings include Eli Lilly, Roche, AstraZeneca, Novo Nordisk, UnitedHealth, Merck and AbbVie.
FundTelligence description · 24/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.
7 of 18 funds ranked on a calculated return
#7/ 18Year to date
+9.06% NOK
as of 13 Nov 2026 · NOK class
About the figures
13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#5/ 221 year
+15.61% NOK
as of 13 Nov 2026 · NOK class
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#7/ 223 years (ann.)
+8.38% NOK
as of 13 Nov 2026 · NOK class
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#1/ 225 years (ann.)
+9.23% NOK
as of 13 Nov 2026 · NOK class
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
Comparison basis
Year to date
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
1 year
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
3 years (ann.)
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
5 years (ann.)
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.